Express Diagnostics News
Express Diagnostics Int’l opens new subsidiary in Bulgaria to serve EMEA
Express Diagnostics Int’l, Inc. (EDI), FDA-registered and ISO 13485:2003-certified medical device manufacturer, today announces the formation of Express Diagnostics Global, Ltd. (EDG), a new subsidiary based in Sofia, Bulgaria. Central to a strategic plan to deliver increased production capacity and enhanced support to distributors in the EMEA region (Europe, the Middle East, Africa), EDG will dedicate manufacturing at its Sofia facility primarily to satisfying EMEA demand for EDI’s DrugCheck® onsite drugs of abuse screening devices.
Express Diagnostics Global’s startup is in the second stage of implementation, with construction, equipment acquisition, and staffing proceeding for a scheduled January 2016 start of medical device production, incorporating advanced manufacturing and quality systems designed to global standards. The subsidiary is operating in partnership with Royal Medical Supplies Pty. Ltd. – exclusive distributor of DrugCheck product in Australia and New Zealand – based in Sydney, Australia.
“We are very excited to announce the start of operations at Express Diagnostics Global,” says Paul Johnson, CEO of Express Diagnostics Int’l. “Establishing this new subsidiary in Bulgaria offers Express Diagnostics several strategic advantages in pursuing accelerated growth with our EMEA distributors, including expanded production capacity and reduced lead and shipping times within the EMEA.
“In addition to opportunities presented by the extra capacity and physical location of the EDG-Bulgaria facility, is the potential of the skilled, available workforce in Sofia,” adds Johnson. “Throughout the process of initial fact-finding to the current preliminary hiring stage, the quality of the people, candidates for employment, and in-country consultants our team has encountered is unsurpassed. We look forward to a long, mutually-beneficial relationship with the people of Sofia.”
Express Diagnostics International’s catalog of products satisfies two distinct, accelerating trends in both healthcare and non-diagnostic screening: focus on cost control and the desire for ever-faster results. With accuracy comparable to laboratory testing, EDI onsite screening devices provide a variety of industries fast, cost-effective alternatives to higher-priced lab services. As a result, continually growing orders from long-standing customers has stretched the production capacity of EDI’s Blue Earth, Minn., facility in terms of locally-available workforce, due in part to the state’s historically low unemployment rate.
The added capacity available through Express Diagnostics Global will free up production-line time at EDI’s Minnesota facility and enable manufacturing dedicated to North American, South American, and Pacific Rim distributors. EDI estimates that Express Diagnostics Global’s proximity to EMEA customers, relative to its Minnesota facility, will cut shipping times by up to 40 percent, with corresponding reductions in shipping costs. Due to anticipated reductions in both product lead times and shipping costs, EDG forecasts subsequent EMEA sales growth will necessitate the recurring addition of production staff at its Sofia facility through at least December 2018.
Express Diagnostics Global’s manufacturing facility is located at 8, Iliansko Shose Street, Sofia 1220, Bulgaria.
Express Diagnostics joins Inc. 5000 for the third year in a row
For the third year in a row, Inc. magazine has named Express Diagnostics Int’l (EDI) to its annual Inc. 5000 list of fastest-growing companies in the U.S. Express Diagnostics, listed at #4354 on the 2015 Inc. 5000, manufactures and distributes DrugCheck® onsite drugs of abuse tests, as well as a growing line of rapid alcohol screening and health diagnostics devices.
“We are very honored to be named again to the Inc. 5000,” says Paul Johnson, CEO of Express Diagnostics. “Making this prestigious list three years in a row is a true testament to the combined efforts of our dedicated employees, customer-partners, and valued suppliers. I’d like to express my appreciation to each of them for the role they’ve played in our continued growth, demonstrated in part by our successive listings on the Inc. 5000.”
Express Diagnostics Int’l joins well-known companies such as Anytime Fitness, FitBit, and GoDaddy.com as 2015 Inc. 5000 honorees.
Founded in 2004, Express Diagnostics has distribution partners in over 60 countries, including distributors with exclusivity in Australia and Mexico. EDI also has company representatives in California, Colorado, Massachusetts, and Sofia, Bulgaria.
About the Inc. 5000
The 2015 Inc. 500 | 5000 is ranked according to percentage revenue growth from 2011 to 2014. To qualify, companies must have been founded and generating revenue by March 31, 2011. They had to be U.S.-based, privately held, for profit, and independent – not subsidiaries or divisions of other companies – as of December 31, 2014. The minimum revenue required for 2011 is $100,000 and $2 million for 2014. Companies on the Inc. 5000 are featured in the magazine’s September issue and online.
Express Diagnostics hosting an open house and job fair July 1
Express Diagnostics Int’l (EDI) in Blue Earth, Minn., is pleased to announce an open house and job fair to be held Wednesday, July 1 from 5:30 to 7:30 p.m. at the EDI headquarters at 1550 Industrial Drive. The public and interested job seekers are invited to stop by the facility for free hamburgers and lemonade, facility tours, and a chance to win one of five Canon color image scanners — a $350 total value.
The job fair aspect of the event focuses on open positions for device Assembly Technicians. Express Diagnostics is offering up to a $500 hiring bonus to each individual hired as an Assembly Technician, as well as additional ongoing bonus opportunities for personal attendance, department performance, and hiring referrals.
Guests are also invited to tour Express Diagnostics’ office, warehouse, and an expanded production area, which is in the process of receiving new device assembly lines to accommodate the company’s continual growth, evidenced by its inclusion on the 2013 and 2014 Inc. 5000 lists of fastest-growing companies in the U.S.
Express Diagnostics featured in Business In Focus article
Express Diagnostics was featured in the March 2015 issue of Business In Focus magazine (Link to article).
Express Diagnostics receives patent for onsite saliva drug test
Express Diagnostics Int’l today announced that its patent for the DrugCheck® SalivaScan™ Oral Fluid Drug Test, titled “Device for Verifying Analytes in Bodily Fluids,” was approved by the European Patent Office. The patent is currently pending with the U.S. Patent and Trademark Office (USPTO Patent Publication Application Number: 20130022517).
“I am more than elated to announce that the first of many patents for the DrugCheck SalivaScan Oral Fluid Drug Test – the European patent – has been granted and published,” says Paul Johnson, CEO of Express Diagnostics Int’l, Inc. “This is a significant milestone for Express Diagnostics. The granting of this patent, and the expected forthcoming U.S. patent, represents another asset in our intellectual property portfolio and in the value we are gaining as a company.
“With the issuance of the European patent, we fully expect the U.S. patent – the most valuable patent – to be granted and published in early 2015.” Adds Johnson, “Again, this is a great accomplishment for Express Diagnostics. I’d like to thank everyone for their work in both the product development and patent application processes, and most importantly, for our customers’ continued support of this innovative product.”
Leading features of the DrugCheck SalivaScan include an integrated sponge saturation indicator in the collection swab that notifies test administrators when sufficient specimen has been collected. Determining adequate specimen according to the color change on the indicator strip helps reduce the potential costs of test failure due to insufficient specimen often associated with competing saliva devices.
The collection swab locks into the DrugCheck SalivaScan for a tamper-evident seal. The device can then be sent to a laboratory for confirmation, on a presumptive positive result. Dual side extraction ports simplify specimen access for laboratory personnel.
The device can screen simultaneously for up to 10 drugs of abuse, with 16 total available, including market-leading cutoffs, or detection levels, for buprenorphine, cotinine, EDDP, ketamine, and methadone. Express Diagnostics manufactures the DrugCheck SalivaScan at its ISO 13485:2003-certified facility in Blue Earth, Minn.
The DrugCheck SalivaScan is for Forensic Use or export only. Forensic Use in the U.S. is limited to criminal justice or government agencies, including correction centers, court systems, jails, police departments, probation offices, the Department of Defense, U.S. military, and laboratories performing forensic testing for these entities.
(top of page)